Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067328
  • December 2021
  • Healthcare
  • 214 Pages
Report Description

This report is a comprehensive study that examines the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry in depth. With reference to key regions and major nations, the study specifies the product type of Chimeric Antigen Receptor (CAR) T-Cell Therapy as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Chimeric Antigen Receptor (CAR) T-Cell Therapy market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market study. The market dynamics and factors such as the threat of a Chimeric Antigen Receptor (CAR) T-Cell Therapy substitute, the threat of new entrants into the Chimeric Antigen Receptor (CAR) T-Cell Therapy market, buyer bargaining power, supplier bargaining power to Chimeric Antigen Receptor (CAR) T-Cell Therapy providing companies, and internal rivalry among Chimeric Antigen Receptor (CAR) T-Cell Therapy providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Chimeric Antigen Receptor (CAR) T-Cell Therapy market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry.
 
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Key Trends Analysis

The important factors influencing the growth of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market have been examined in this report. The driving factors that are boosting demand for Chimeric Antigen Receptor (CAR) T-Cell Therapys and the restraining factors that are slowing growth of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry are addressed in depth, as well as their implications for the worldwide Chimeric Antigen Receptor (CAR) T-Cell Therapy market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry. On the basis of current and future trends, all segments of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Chimeric Antigen Receptor (CAR) T-Cell Therapy market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Chimeric Antigen Receptor (CAR) T-Cell Therapy market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. All important stakeholders in the Chimeric Antigen Receptor (CAR) T-Cell Therapy value chain and technological ecosystem are expected to benefit from the insights offered in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market research study.

In order to provide a broader understanding of the top competitors in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market, the research includes a company market share analysis. Abbvie Inc., Amgen, AstraZeneca, Avacta Life Sciences Ltd., Bellicum Pharmaceuticals, Bluebird Bio, Bristol Myers Squibb, Cellectis, Celyad SA, Editas Medicine Inc., Eureka Therapeutics Inc., F. Hoffman-La Roche AG, Formula Pharmaceuticals Inc., Gilead Sciences, Icell Gene Therapeutics, Mustang Bio Inc., Noile-Immune Biotech, Novartis AG, Protheragen Inc., Puretech Health, Servier Laboratories, Takeda Pharmaceuticals, Transgene SA are among the major participants in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Abbvie Inc., Amgen, AstraZeneca, Avacta Life Sciences Ltd., Bellicum Pharmaceuticals, Bluebird Bio, Bristol Myers Squibb, Cellectis, Celyad SA, Editas Medicine Inc., Eureka Therapeutics Inc., F. Hoffman-La Roche AG, Formula Pharmaceuticals Inc., Gilead Sciences, Icell Gene Therapeutics, Mustang Bio Inc., Noile-Immune Biotech, Novartis AG, Protheragen Inc., Puretech Health, Servier Laboratories, Takeda Pharmaceuticals, Transgene SA
 
Major Highlights of the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market report study:
  • An in-depth examination of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy industry will be published soon.
  • The study examines the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Chimeric Antigen Receptor (CAR) T-Cell Therapy industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market is being shaped by several major trends.
  • The size of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Chimeric Antigen Receptor (CAR) T-Cell Therapy market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market as follows:
Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: By Product Type

  • Type I
  • Type II
  • Type III

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: By Application
  • Application I
  • Application II
  • Application III

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Chimeric Antigen Receptor (CAR) T-Cell Therapy market.
  • Universities and students
  • Other companies in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Chimeric Antigen Receptor (CAR) T-Cell Therapy market

Manufacturers and Segments

  • Abbvie Inc.
  • Amgen
  • AstraZeneca
  • Avacta Life Sciences Ltd.
  • Bellicum Pharmaceuticals
  • Bluebird Bio
  • Bristol Myers Squibb
  • Cellectis
  • Celyad SA
  • Editas Medicine Inc.
  • Eureka Therapeutics Inc.
  • F. Hoffman-La Roche AG
  • Formula Pharmaceuticals Inc.
  • Gilead Sciences
  • Icell Gene Therapeutics
  • Mustang Bio Inc.
  • Noile-Immune Biotech
  • Novartis AG
  • Protheragen Inc.
  • Puretech Health
  • Servier Laboratories
  • Takeda Pharmaceuticals
  • Transgene SA
  • Type I
  • Type II
  • Type III
  • Application I
  • Application II
  • Application III

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Snapshot
          2.1.1. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market By Type I,2019
               2.1.1.1.
               2.1.1.2.Type I I
               2.1.1.3.Type I II
          2.1.2. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market By Application I,2019
               2.1.2.1.
               2.1.2.2.Application I I
               2.1.2.3.Application I II
          2.1.3. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market By End-use,2019
          2.1.4. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market By Geography,2019

3. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Type I, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type I, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type I, 2020
     4.2. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Type I, 2018 – 2028

5. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Application I, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application I, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application I, 2020
     5.2. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Application I, 2018 – 2028

6. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By End-use, 2018 – 2028

7. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Analysis, 2018 – 2028 
          7.2.1. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Type I, 2018 – 2028
          7.2.3. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Application I, 2018 – 2028
          7.2.4. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Analysis, 2018 – 2028 
          7.3.1.  Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Type I, 2018 – 2028
          7.3.3. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Application I, 2018 – 2028
          7.3.4. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Type I, 2018 – 2028
          7.4.3. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Application I, 2018 – 2028
          7.4.4. Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Type I, 2018 – 2028
          7.5.3. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Application I, 2018 – 2028
          7.5.4. Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Analysis, 2018 – 2028 
          7.6.1.  MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Type I, 2018 – 2028
          7.6.3. MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By Application I, 2018 – 2028
          7.6.4. MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Chimeric Antigen Receptor (CAR) T-Cell Therapy Providers
        8.4.1 Abbvie Inc.
                8.4.1.1 Business Description
                8.4.1.2 Abbvie Inc. Geographic Operations
                8.4.1.3 Abbvie Inc. Financial Information
                8.4.1.4 Abbvie Inc. Product Positions/Portfolio
                8.4.1.5 Abbvie Inc. Key Developments
        8.4.2 Amgen
                8.4.2.1 Business Description
                8.4.2.2 Amgen Geographic Operations
                8.4.2.3 Amgen Financial Information
                8.4.2.4 Amgen Product Positions/Portfolio
                8.4.2.5 Amgen Key Developments
        8.4.3 AstraZeneca
                8.4.3.1 Business Description
                8.4.3.2 AstraZeneca Geographic Operations
                8.4.3.3 AstraZeneca Financial Information
                8.4.3.4 AstraZeneca Product Positions/Portfolio
                8.4.3.5 AstraZeneca Key Developments
        8.4.4 Avacta Life Sciences Ltd.
                8.4.4.1 Business Description
                8.4.4.2 Avacta Life Sciences Ltd. Geographic Operations
                8.4.4.3 Avacta Life Sciences Ltd. Financial Information
                8.4.4.4 Avacta Life Sciences Ltd. Product Positions/Portfolio
                8.4.4.5 Avacta Life Sciences Ltd. Key Developments
        8.4.5 Bellicum Pharmaceuticals
                8.4.5.1 Business Description
                8.4.5.2 Bellicum Pharmaceuticals Geographic Operations
                8.4.5.3 Bellicum Pharmaceuticals Financial Information
                8.4.5.4 Bellicum Pharmaceuticals Product Positions/Portfolio
                8.4.5.5 Bellicum Pharmaceuticals Key Developments
        8.4.6 Bluebird Bio
                8.4.6.1 Business Description
                8.4.6.2 Bluebird Bio Geographic Operations
                8.4.6.3 Bluebird Bio Financial Information
                8.4.6.4 Bluebird Bio Product Positions/Portfolio
                8.4.6.5 Bluebird Bio Key Developments
        8.4.7 Bristol Myers Squibb
                8.4.7.1 Business Description
                8.4.7.2 Bristol Myers Squibb Geographic Operations
                8.4.7.3 Bristol Myers Squibb Financial Information
                8.4.7.4 Bristol Myers Squibb Product Positions/Portfolio
                8.4.7.5 Bristol Myers Squibb Key Developments
        8.4.8 Cellectis
                8.4.8.1 Business Description
                8.4.8.2 Cellectis Geographic Operations
                8.4.8.3 Cellectis Financial Information
                8.4.8.4 Cellectis Product Positions/Portfolio
                8.4.8.5 Cellectis Key Developments
        8.4.9 Celyad SA
                8.4.9.1 Business Description
                8.4.9.2 Celyad SA Geographic Operations
                8.4.9.3 Celyad SA Financial Information
                8.4.9.4 Celyad SA Product Positions/Portfolio
                8.4.9.5 Celyad SA Key Developments
        8.4.10 Editas Medicine Inc.
                8.4.10.1 Business Description
                8.4.10.2 Editas Medicine Inc. Geographic Operations
                8.4.10.3 Editas Medicine Inc. Financial Information
                8.4.10.4 Editas Medicine Inc. Product Positions/Portfolio
                8.4.10.5 Editas Medicine Inc. Key Developments
        8.4.11 Eureka Therapeutics Inc.
                8.4.11.1 Business Description
                8.4.11.2 Eureka Therapeutics Inc. Geographic Operations
                8.4.11.3 Eureka Therapeutics Inc. Financial Information
                8.4.11.4 Eureka Therapeutics Inc. Product Positions/Portfolio
                8.4.11.5 Eureka Therapeutics Inc. Key Developments
        8.4.12 F. Hoffman-La Roche AG
                8.4.12.1 Business Description
                8.4.12.2 F. Hoffman-La Roche AG Geographic Operations
                8.4.12.3 F. Hoffman-La Roche AG Financial Information
                8.4.12.4 F. Hoffman-La Roche AG Product Positions/Portfolio
                8.4.12.5 F. Hoffman-La Roche AG Key Developments
        8.4.13 Formula Pharmaceuticals Inc.
                8.4.13.1 Business Description
                8.4.13.2 Formula Pharmaceuticals Inc. Geographic Operations
                8.4.13.3 Formula Pharmaceuticals Inc. Financial Information
                8.4.13.4 Formula Pharmaceuticals Inc. Product Positions/Portfolio
                8.4.13.5 Formula Pharmaceuticals Inc. Key Developments
        8.4.14 Gilead Sciences
                8.4.14.1 Business Description
                8.4.14.2 Gilead Sciences Geographic Operations
                8.4.14.3 Gilead Sciences Financial Information
                8.4.14.4 Gilead Sciences Product Positions/Portfolio
                8.4.14.5 Gilead Sciences Key Developments
        8.4.15 Icell Gene Therapeutics
                8.4.15.1 Business Description
                8.4.15.2 Icell Gene Therapeutics Geographic Operations
                8.4.15.3 Icell Gene Therapeutics Financial Information
                8.4.15.4 Icell Gene Therapeutics Product Positions/Portfolio
                8.4.15.5 Icell Gene Therapeutics Key Developments
        8.4.16 Mustang Bio Inc.
                8.4.16.1 Business Description
                8.4.16.2 Mustang Bio Inc. Geographic Operations
                8.4.16.3 Mustang Bio Inc. Financial Information
                8.4.16.4 Mustang Bio Inc. Product Positions/Portfolio
                8.4.16.5 Mustang Bio Inc. Key Developments
        8.4.17 Noile-Immune Biotech
                8.4.17.1 Business Description
                8.4.17.2 Noile-Immune Biotech Geographic Operations
                8.4.17.3 Noile-Immune Biotech Financial Information
                8.4.17.4 Noile-Immune Biotech Product Positions/Portfolio
                8.4.17.5 Noile-Immune Biotech Key Developments
        8.4.18 Novartis AG
                8.4.18.1 Business Description
                8.4.18.2 Novartis AG Geographic Operations
                8.4.18.3 Novartis AG Financial Information
                8.4.18.4 Novartis AG Product Positions/Portfolio
                8.4.18.5 Novartis AG Key Developments
        8.4.19 Protheragen Inc.
                8.4.19.1 Business Description
                8.4.19.2 Protheragen Inc. Geographic Operations
                8.4.19.3 Protheragen Inc. Financial Information
                8.4.19.4 Protheragen Inc. Product Positions/Portfolio
                8.4.19.5 Protheragen Inc. Key Developments
        8.4.20 Puretech Health
                8.4.20.1 Business Description
                8.4.20.2 Puretech Health Geographic Operations
                8.4.20.3 Puretech Health Financial Information
                8.4.20.4 Puretech Health Product Positions/Portfolio
                8.4.20.5 Puretech Health Key Developments
        8.4.21 Servier Laboratories
                8.4.21.1 Business Description
                8.4.21.2 Servier Laboratories Geographic Operations
                8.4.21.3 Servier Laboratories Financial Information
                8.4.21.4 Servier Laboratories Product Positions/Portfolio
                8.4.21.5 Servier Laboratories Key Developments
        8.4.22 Takeda Pharmaceuticals
                8.4.22.1 Business Description
                8.4.22.2 Takeda Pharmaceuticals Geographic Operations
                8.4.22.3 Takeda Pharmaceuticals Financial Information
                8.4.22.4 Takeda Pharmaceuticals Product Positions/Portfolio
                8.4.22.5 Takeda Pharmaceuticals Key Developments
        8.4.23 Transgene SA
                8.4.23.1 Business Description
                8.4.23.2 Transgene SA Geographic Operations
                8.4.23.3 Transgene SA Financial Information
                8.4.23.4 Transgene SA Product Positions/Portfolio
                8.4.23.5 Transgene SA Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Type I, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By Application I, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy: Market Segmentation 
FIG. 2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Type I, 2019 (US$ Mn) 
FIG. 5 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Application I, 2019 (US$ Mn) 
FIG. 6 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Chimeric Antigen Receptor (CAR) T-Cell Therapy Providers, 2019
FIG. 11 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue Contribution, By Type I, 2019 & 2028 (Value %) 
FIG. 12 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue Contribution, By Application I, 2019 & 2028 (Value %) 
FIG. 13 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment1, 2018 – 2028
TABLE  North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment2, 2018 – 2028
TABLE  North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Country, 2018 – 2028
TABLE  Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment1, 2018 – 2028
TABLE  Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment2, 2018 – 2028
TABLE  Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Country, 2018 – 2028
TABLE  Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Country, 2018 – 2028
TABLE  MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment1, 2018 – 2028
TABLE  MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Segment2, 2018 – 2028
TABLE  MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, By Country, 2018 – 2028
TABLE  Abbvie Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Amgen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Avacta Life Sciences Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bellicum Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bluebird Bio: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol Myers Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cellectis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Celyad SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Editas Medicine Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eureka Therapeutics Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffman-La Roche AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Formula Pharmaceuticals Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Gilead Sciences: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Icell Gene Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mustang Bio Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Noile-Immune Biotech: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Protheragen Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Puretech Health: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Servier Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Takeda Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Transgene SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, By Geography, 2019 (US$ Mn)
FIG.  Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Chimeric Antigen Receptor (CAR) T-Cell Therapy Providers, 2016
FIG.  Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Type I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Type III Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Application I Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application II Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Application III Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Value, 2018 – 2028, (US$ Mn)